News

Our AMD (NASDAQ:AMD) call is one of the tougher ones we’ve made this quarter. The stock has done what few thought possible, doubling in months on the back of an AI accelerator story that is finally landing with hyperscalers. The 24/7 Wall St. price target for AMD is $480.90 over the next 12 months, roughly […]

After spending a few hours researching available promotions, a redditor strategized how to earn nearly $3,500 in bonus cash from checking account openings.

C expects 2026 ROTCE to exceed 11% as stronger client activity, cost savings and capital productivity support returns.

Moby summary of Vera Bradley, Inc.'s Q2 2027 earnings call

Qualcomm's automotive and data center businesses are quietly rewriting the company's story while everyone debates the Apple modem loss, and that tension is exactly why the buy button keeps getting hit.

Over the last six months, Yum! Brands’s shares have sunk to $145.90, producing a disappointing 9.8% loss - a stark contrast to the S&P 500’s 14.2% gain. This may have investors wondering how to approach the situation.

On Sept. 15, 2026, technology stocks face headwinds while rising crude weighs on industrials.

People in their 30s may need to invest less than $500 per month to be on track to retire with $1 million.

On September 10, Canaccord cut its price target for The Lovesac Company (NASDAQ:LOVE) from $22 to $20 but maintained its Buy rating on the stock. This update came after the company reported its financial results for the second quarter of fiscal 2027, which ended August 2, 2026. Canaccord noted that the company’s fiscal Q2 results […]

The Alibaba-owned e-commerce platform made a case for toys and plushes that defy conventional beauty during a playful exhibition in Hangzhou.

Casey’s shares sank after earnings, but Bank of America sees the selloff creating an opening as temporary pressures cloud stronger trends.

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.

Treasury Secretary Scott Bessent is doubling down on his persona as an interventionist, signaling a willingness to use the "necessary tools" to support the bond market. The bond market is under pressure. Ten-year Treasury yields are threatening to close at levels not seen since 2007.

The eVTOL sector keeps bleeding out, and Joby, Archer, and EHang are all hovering near 52-week lows with no single catalyst to blame. What happens next depends on a certification outcome that could either reprice the entire thesis overnight or make the next capital raise painfully expensive.

Shares of Axon Enterprise declined sharply Tuesday and were the worst performers in the after the Taser maker announced plans to raise $1 billion, and potentially more, in debt. Goldman Sachs, Morgan Stanley, JPMorgan Securities, RBC Capital Markets, and Citigroup will be serving as joint managers of the offering. Axon has faced broader concerns about disruption by artificial intelligence and a decline in operating income throughout fiscal 2025, and shares have declined 41% over the last 12 months.

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Steve Eisman’s former “Big Short” partners are warning that the wave of giant IPOs could put pressure on stocks by flooding the market with new shares. Porter Collins and Vincent Daniel, who worked with Eisman at FrontPoint during the famous...

Elon Musk is promising a Tesla reveal so extraordinary it requires a live audience to prove it isn't AI-generated, but prediction markets are quietly telling a very different story about what actually happens next.

Find insight on global auto sales, Volkswagen and more in the latest Market Talks covering Auto and Transport.

Find insight on Enbridge, oil futures, SK Innovation, and more in the latest Market Talks covering Energy and Utilities.

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Darden Restaurants (DRI) is expected to see an improving earnings trajectory as trends at its Olive

SAPMF secures a $350M subsea contract for Angola's West Hub Tails project, covering equipment, installation and tieback work to the Agogo FPSO.

It’s only the tenth trading day of September, but the major stock market indexes are already in quite a hole. The Dow, down 2.4% so far this month, is on pace for its worst 10-day start to September since 2008, according to Dow Jones Market Data. The S&P 500 and Nasdaq Composite, down 1.4% each, are on pace for their worst start to September since 2020 and 2023, respectively.

Find insight on Australian banks, Indonesian state-owned banks and more in the latest Market Talks covering Financial Services.

UiPath's 21% rise in million-dollar customers highlights deeper enterprise adoption, even as the stock falls and competition in AI automation stays intense.

Cancer progress, a broader pipeline and vaccine expansion help MRNA rebuild beyond COVID-19, but can oncology drive its next growth phase?

Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN) reported on August 14 that the European Medicines Agency has validated the Marketing Authorization Application for PF-07307405, the companies’ experimental Lyme disease vaccine candidate, and will now begin the official review. For a vaccine candidate first proposed in a 2020 collaboration deal between Pfizer Inc. (NYSE:PFE) and French […]

A landmark trial just proved semaglutide can pull children as young as six below the obesity threshold, yet Wall Street shrugged and the real battle over who pays, who prescribes, and whether society is ready has barely begun.